UNCY
Unicycive Therapeutics Inc
NASDAQ: UNCY · HEALTHCARE · BIOTECHNOLOGY
$7.16
-0.14% today
Updated 2026-04-29
Market cap
$180.96M
P/E ratio
—
P/S ratio
23.75x
EPS (TTM)
$-1.67
Dividend yield
—
52W range
$4 – $11
Volume
0.5M
Unicycive Therapeutics Inc (UNCY) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $951000.00 | $675000.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | -29.0% | -100.0% | — |
| Cost of revenue | — | — | — | $1000.00 | $7000.00 | $284000.00 | $428000.00 | $572000.00 |
| Gross profit | — | — | — | $-1000.00 | $951000.00 | $675000.00 | $-428000.00 | $-572000.00 |
| Gross margin | — | — | — | — | 100.0% | 100.0% | — | — |
| R&D | $344000.00 | $795000.00 | $1.01M | $6.08M | $12.44M | $12.90M | $20.01M | $9.12M |
| SG&A | $608000.00 | $1.17M | $1.00M | $2.90M | $6.57M | $8.55M | $12.10M | $20.40M |
| Operating income | $-952000.00 | $-1.96M | $-2.02M | $-8.98M | $-18.05M | $-20.77M | $-32.12M | $-29.52M |
| Operating margin | — | — | — | — | -1898.2% | -3077.6% | — | — |
| EBITDA | — | $-2.03M | $-2.02M | $-8.96M | $-17.89M | $-30.18M | $-36.23M | $-25.91M |
| EBITDA margin | — | — | — | — | -1881.3% | -4470.8% | — | — |
| EBIT | $-952000.00 | $-1.96M | $-2.02M | $-8.98M | $-18.05M | $-30.46M | $-36.66M | $-26.48M |
| Interest expense | $0.00 | $139000.00 | $244000.00 | $628000.00 | $6000.00 | $82000.00 | $71000.00 | $71000.00 |
| Income tax | $-952000.00 | $139000.00 | $244000.00 | $615000.00 | $6000.00 | $116105.00 | $-1.09M | — |
| Effective tax rate | 45.9% | -6.4% | -10.8% | -6.1% | -0.0% | -0.4% | 2.9% | 0.0% |
| Net income | $-1.12M | $-2.30M | $-2.51M | $-10.63M | $-18.06M | $-30.54M | $-36.73M | $-26.55M |
| Net income growth (YoY) | — | -105.7% | -8.9% | -323.9% | -69.9% | -69.1% | -20.2% | +27.7% |
| Profit margin | — | — | — | — | -1899.5% | -4525.0% | — | — |